An observational study in COVID-19 and Vitamin D Deficiency, sponsored by Tameside General Hospital. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-07.
Sponsored by Tameside General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 340 studies in COVID-19 with a site in United Kingdom — 17 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · United Kingdom.
Among the 340 studies in COVID-19 with a site in United Kingdom, this one is the 53rd largest by enrollment of the 167 observational ones that give a count, is one of 192 that started in 2020, is one of 167 observational ones, and was the 60th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →17 of the 340 studies in COVID-19 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–50 · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Technical University of Munich · Sites in United Kingdom, Austria, Belgium and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
340 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 52 · Phase 3 66 · Phase 4 5
First in 2013; this study’s year is marked. 192 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 986 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 247 across the 172 interventional studies, 296 across the 167 observational. Of the 245 that completed or were terminated, 75 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 340 have an industry lead sponsor. The 10 most frequent:
Tameside General Hospital is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Tameside General Hospital has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
5 of the studies in COVID-19 with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03188796Phase 3Medical University of GrazThe VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients | 2027-07 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
| NCT04863573Queen's University, BelfastCOVID-19 Antibody Responses In Cystic Fibrosis | 2027-08 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 340 studies in COVID-19 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The 2019 novel coronavirus disease (COVID-2019) pandemic is an enormous health issue of worldwide scale. Prevention and/or treatment with a widely-available and already-licensed product such as vitamin D (cholecalciferol) could have a large impact on healthcare worldwide. Given ethnic variation in vitamin D production, this could help to address the discrepancies in how people of different ethnicities are affected by COVID-19. There are currently no published studies analysing either individual-level evidence on the effect of vitamin D status on COVID-19 outcomes, or any prospective studies planning on following-up patients with reference to vitamin D and COVID-19 infection.
The study will have 2 arms. Arm 1 will recruit patients hospitalised with COVID-19. Vitamin D levels will be measured in these patients and compared with outcome measures of COVID-19 severity. In Arm 2, patients will be recruited prospectively from local general practices (GPs) with measurement of vitamin D levels at enrolment. They will be followed up after 6 months to determine whether baseline vitamin D levels correspond with developing COVID-19. Data will be collected from a mixture of patient medical records, electronic patient records, laboratory data and from patients themselves. Data in Arm 1 will be analysed with a combination of linear and logistic regression, as appropriate, and with adjustment for covariates. Data in Arm 2 will be analysed as a case-control study, with adjustment for covariates.
The primary objectives are to determine whether vitamin D levels affect outcomes in COVID-19 infection and whether vitamin D deficiency is associated with increased risk.
STUDY DESIGN Arm 1: Hospital in-patients with a clinical diagnosis of COVID-19 This will be an observational cohort study of patients hospitalised at Tameside General Hospital with a clinical diagnosis of COVID-19, as defined by the clinical coding department. Patient identifiers will be extracted by the coding department and held on a secure server at Tameside Hospital. Identifiers will be used to ensure serum samples already taken as part of routine clinical management of these patients can be processed for a vitamin D level. No additional blood samples will need to be taken.
Patient demographic details will be extracted from their clinical notes and electronic patient records, then placed on an anonymised database for analysis. Data will be analysed to determine the following:
Projected recruitment is 200 patients to be opportunistically recruited who are undergoing usual clinical care for COVID-19.
Arm 2: Primary care patients prospectively studied with reference to baseline vitamin D and risk of COVID-19 Patients will be prospectively recruited from local GP surgeries within the Tameside and Glossop Clinical Commissioning Group. Patients will be consented by Good Clinical Practice (GCP)-certified practitioners. A serum sample will be collected on recruitment for a baseline vitamin D level to be obtained. Patient contact details will be collected, as well as baseline health status and comorbidities, then stored on an encrypted database on a secure server at Tameside Hospital. Vitamin D levels will be communicated to GP surgeries and GPs can decide whether to treat patients according to local treatment guidelines for suboptimal vitamin D. After 6 months, patients will be followed-up via telephone interview, in order to ascertain whether they have developed COVID-19, any treatment outcomes for this, and whether they have been treated with vitamin D in the interim in primary/secondary/tertiary care.
Data will be analysed once all recruited patients have been followed-up after 6 months. At follow-up, patients who have developed COVID-19 will be deemed to be cases, and those who have not will be deemed to be controls, for a case-control analysis using vitamin D levels as an exploratory covariate. It is anticipated that there will be some patient drop-out, but compliance with follow-up is likely to be high, due to the use of a telephone interview. Analysis will aim to determine whether vitamin D levels are associated with the risk of developing COVID-19, with reference to additional covariates, such as ethnicity and comorbidity.
Projected recruitment is 800 patients to be opportunistically recruited who are attending their GP surgery for routine care, not necessarily related to COVID-19.
INCLUSION CRITERIA Arm 1
Inclusion criteria:
Exclusion criteria:
Arm 2
Inclusion criteria:
Exclusion criteria:
ANALYSIS Arm 1
Mean values of age and gender, as well as proportions of different ethnic groups, will be used to assess group comparability. Primary analysis will involve linear regression of vitamin D levels (as a continuous variable, with adjustment for age and gender) against variables representing COVID-19 treatment outcomes:
Primary analysis will also include logistic regression of ethnic groups against the above treatment outcome variables, with adjustment for age, gender and vitamin D status.
The following variables will be included as additional predictors of severity:
The following variables will be included as covariates:
Linear regression will be reported as a coefficient with a 95% confidence interval. Logistic regression will be reported as an adjusted odds ratio with a 95% confidence interval. Missing data will be imputed. Analysis will be carried out once all data has been collected for n=200 patients and serum vitamin D levels are available.
Arm 2
Mean values of age and gender, as well as proportions of different ethnic groups, will be used to assess group comparability. Once all data has been collected, patients who developed COVID-19 will be defined as "cases" and those who did not will be defined as "controls." A case-control study including vitamin D as a predictor variable will then be carried out, with statistics reported as an adjusted odds ratio with a 95% confidence interval. Further subanalysis will be carried out on the following outcome measures (again, being defined as a "case"):
The following variables will be included as additional predictors of severity:
The following variables will be included as covariates:
Missing data at enrolment will be imputed. Patients lost to follow-up will have baseline data included and they will be treated as a "control." Analysis will be carried out once all follow-up data has been collected for n=800 patients recruited.
ARM 1 Patients will be opportunistically recruited from in-patient admissions with a clinical diagnosis of COVID-19 as registered by the Trust's clinical coding department. This will be carried out at a single centre (Tameside and Glossop Integrated Care NHS Foundation Trust).
ARM 2 Patients will be opportunistically recruited from 10 local GP surgeries feeding into the acute Trust, as part of the Tameside and Glossop Clinical Commissioning Group.
ARM 1 - hospital in-patients
Inclusion Criteria:
Exclusion Criteria:
ARM 2 - prospective primary care case-control study
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cross-sectional study of hospital in-patients admitted with COVID-19 n=200
Case-control study of n=800 patients prospectively recruited from primary care
Case-control study of n=800 patients prospectively recruited from primary care
COVID-19 infection
Development of COVID-19 during case-control study
Time frame: 1 year
Oxygen therapy for COVID-19
Whether hospitalised COVID-19 patients require oxygen therapy
Time frame: 1 year
Discharge following COVID-19 hospitalisation
Whether patients hospitalised with COVID-19 were discharged
Time frame: 1 year
Death due to COVID-19
Whether patients hospitalised with COVID-19 died in hospital
Time frame: 1 year
Ran from Jun 2020 to primary completion in Aug 2020, 2 months.
Of 1,641 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 2 months is below that.
Counting every sponsor, half of 1,775 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tameside General Hospital